Ultrafiltration and subsequent high performance liquid chromatography for in vivo determinations of the protein binding of etoposide
- 1 August 1996
- journal article
- research article
- Published by Elsevier in Cancer Letters
- Vol. 106 (1) , 91-96
- https://doi.org/10.1016/0304-3835(96)04307-8
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- High-performance liquid chromatography with fluorometric detection for monitoring of etoposide and its cis-isomer in plasma and leukaemic cellsJournal of Chromatography B: Biomedical Sciences and Applications, 1995
- Etoposide: current status and future perspectives in the management of malignant neoplasmsCancer Chemotherapy and Pharmacology, 1994
- In Vivo Accumulation of Etoposide in Peripheral Leukemic Cells in Patients Treated for Acute Myeloblastic Leukemia; Relation to Plasma Concentrations and Protein BindingLeukemia & Lymphoma, 1993
- Relation of systemic exposure to unbound etoposide and hematologic toxicityClinical Pharmacology & Therapeutics, 1991
- Etoposide in leukemia, lymphoma and bone marrow transplantationLeukemia Research, 1989
- Altered protein binding of etoposide in patients with cancerClinical Pharmacology & Therapeutics, 1989
- Mechanism of Action of Antitumor Drug Etoposide: A ReviewJNCI Journal of the National Cancer Institute, 1988
- Etoposide (VP-16–213)New England Journal of Medicine, 1985
- Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatographyJournal of Chromatography B: Biomedical Sciences and Applications, 1980
- Comparison of the human pharmacokinetics of VM-26 and VP-16, two antineoplastic epipodophyllotoxin glucopyranoside derivativesPublished by Elsevier ,1975